MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
1.435
-0.015
-1.03%
Closed 16:00 12/01 EST
OPEN
1.400
PREV CLOSE
1.450
HIGH
1.500
LOW
1.400
VOLUME
20.03K
TURNOVER
0
52 WEEK HIGH
4.180
52 WEEK LOW
1.040
MARKET CAP
16.31M
P/E (TTM)
-0.2342
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TARA last week (1127-1201)?
Weekly Report · 1h ago
Oppenheimer Reaffirms Their Buy Rating on Protara Therapeutics (TARA)
TipRanks · 3d ago
Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)
TipRanks · 3d ago
Protara Therapeutics Announces Presentation Of Additional Encouraging Data From Phase 1a ADVANCED-1 Trial Of TARA-002 In NMIBC At The 24th Annual Meeting Of The Society Of Urologic Oncology
New results from six patients with hgta papillary tumors show five of six students with hgrfs at week 12 data continue to support favorable tolerability of tara-002 in patients with nmibc. Anti-tumor activity observed in all three evaluable patients with cis, including one heavily pre-treated bcg-unresponsive patient who achieved a complete response. Data will be presented at the 24th annual meeting of the society of urologic oncology.
Benzinga · 3d ago
Weekly Report: what happened at TARA last week (1120-1124)?
Weekly Report · 11/27 11:45
Weekly Report: what happened at TARA last week (1113-1117)?
Weekly Report · 11/20 11:42
Protara Therapeutics Inc: Notice of Effectiveness
Press release · 11/15 16:02
Weekly Report: what happened at TARA last week (1106-1110)?
Weekly Report · 11/13 11:34
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002 and IV Choline Chloride. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. The Company’s IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.